Gary G Schwartz1, Steinar Tretli2, Linda Vos2, Trude E Robsahm3. 1. Department of Population Health, University of North Dakota School of Medicine & Health Sciences, Grand Forks, ND, USA. 2. Department of Research, Cancer Registry of Norway, Oslo, Norway. 3. Department of Research, Cancer Registry of Norway, Oslo, Norway. Electronic address: trude.eid.robsahm@kreftregisteret.no.
Abstract
BACKGROUND: Women with higher serum calcium may be more likely to be diagnosed and die of ovarian cancer. We evaluated that finding in a large, prospective cohort. METHODS: We conducted a nested case-control study using a population-based biobank from Norway. We compared 202 ovarian cancer cases and 202 controls, matched for age, date at blood draw, and county of residence, with respect to serum calcium and albumin, adjusted for anthropometric variables. We evaluated risks using the entire follow-up period as well as 2-15 years and 16-25 years ("early" and "late", respectively). RESULTS: For the entire follow-up, risk was significantly increased in the highest tertile of albumin and for high albumin and calcium jointly. Risks for ovarian cancer differed markedly by follow-up time. In early follow-up, women in the highest tertile of serum calcium had a 2.5-fold increased risk, adjusted for height and body mass index (OR=2.47, 95% C.I. 1.12-5.45) with a significant dose-response (p=0.024). Risk was not elevated in late follow-up (OR=0.62, 95% C.I. 0.27-1.36). Similarly, in early follow-up, women in the highest tertile of serum albumin had an increased risk (OR=2.55, 95% C.I.1.22-5.49) with a significant dose-response (p=0.009). Conversely, risk was not increased in late follow-up (OR=1.36, 95% C.I. 0.65-2.83). CONCLUSIONS: These data confirm a prospective association between higher serum calcium and ovarian cancer. An association in early, but not late, follow-up suggests that the higher calcium reflects the presence of existing cancer. A positive association with serum albumin is novel and should be interpreted cautiously.
BACKGROUND:Women with higher serum calcium may be more likely to be diagnosed and die of ovarian cancer. We evaluated that finding in a large, prospective cohort. METHODS: We conducted a nested case-control study using a population-based biobank from Norway. We compared 202 ovarian cancer cases and 202 controls, matched for age, date at blood draw, and county of residence, with respect to serum calcium and albumin, adjusted for anthropometric variables. We evaluated risks using the entire follow-up period as well as 2-15 years and 16-25 years ("early" and "late", respectively). RESULTS: For the entire follow-up, risk was significantly increased in the highest tertile of albumin and for high albumin and calcium jointly. Risks for ovarian cancer differed markedly by follow-up time. In early follow-up, women in the highest tertile of serum calcium had a 2.5-fold increased risk, adjusted for height and body mass index (OR=2.47, 95% C.I. 1.12-5.45) with a significant dose-response (p=0.024). Risk was not elevated in late follow-up (OR=0.62, 95% C.I. 0.27-1.36). Similarly, in early follow-up, women in the highest tertile of serum albumin had an increased risk (OR=2.55, 95% C.I.1.22-5.49) with a significant dose-response (p=0.009). Conversely, risk was not increased in late follow-up (OR=1.36, 95% C.I. 0.65-2.83). CONCLUSIONS: These data confirm a prospective association between higher serum calcium and ovarian cancer. An association in early, but not late, follow-up suggests that the higher calcium reflects the presence of existing cancer. A positive association with serum albumin is novel and should be interpreted cautiously.
Authors: Jian Yin; Liang-Yu Yin; Neal D Freedman; Ting-Yuan Li; Sanford M Dawsey; Jian-Feng Cui; Philip R Taylor; Bin Liu; Jin-Hu Fan; Wen Chen; Christian C Abnet; You-Lin Qiao Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-08-20 Impact factor: 4.254
Authors: Zhuoyu Yang; Yadi Zheng; Zheng Wu; Yan Wen; Gang Wang; Shuohua Chen; Fengwei Tan; Jiang Li; Shouling Wu; Min Dai; Ni Li; Jie He Journal: Cancer Med Date: 2021-05-26 Impact factor: 4.452